News
BIIB
140.19
-2.42%
-3.47
BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant
NASDAQ · 15h ago
Ionis Out-Licenses Rights for Rare Blood Cancer Drug to Ono
NASDAQ · 19h ago
Sage moved to Underperform at BofA; says Biogen’s buyout impact has passed
Seeking Alpha · 1d ago
IONS/AZN Get FDA Nod for Amyloidosis Drug, Wainzua in Europe
NASDAQ · 1d ago
Biogen Initiates Phase 3 TRANSCEND Study to Evaluate Felzartamab for Late Antibody-Mediated Rejection in Kidney Transplant Recipients
NASDAQ · 1d ago
BRIEF-Biogen Initiates Phase 3 Study Of Felzartamab For The Treatment Of Late Antibody-Mediated Rejection (AMR) In Kidney Transplant Patients
Reuters · 1d ago
Biogen Director Makes a Major Stock Move!
TipRanks · 2d ago
Sage Therapeutics resumed with an Underperform at BofA
TipRanks · 2d ago
Nasdaq 100 Movers: MSTR, GFS
NASDAQ · 2d ago
Early notable gainers among liquid option names on March 10th
TipRanks · 2d ago
Unusually active option classes on open March 10th
TipRanks · 2d ago
Weekly Report: what happened at BIIB last week (0303-0307)?
Weekly Report · 2d ago
Notable healthcare headlines for the week: Walgreens Boots Alliance, AbbVie and Novo Nordisk in focus
Seeking Alpha · 3d ago
Notable Friday Option Activity: BIIB, RBLX, FRPT
NASDAQ · 5d ago
BUZZ- Some defensives outperform, even as indexes switch to gains
Reuters · 5d ago
How Is The Market Feeling About Biogen?
Benzinga · 5d ago
ClearBridge All Cap Growth Strategy Q4 2024 Commentary
Seeking Alpha · 5d ago
SLDB Stock Rallies 60% in a Month: Here's What You Should Know
NASDAQ · 5d ago
Alzheimer's Drugs From Eli Lilly And Biogen Still Deemed Too Costly For NHS Funding
Benzinga · 6d ago
Biogen (BIIB) Receives a Hold from Bernstein
TipRanks · 03/06 06:56
More
Webull provides a variety of real-time BIIB stock news. You can receive the latest news about Biogen Inc through multiple platforms. This information may help you make smarter investment decisions.
About BIIB
Biogen Inc. is a global biopharmaceutical company. The Company is focused on discovering, developing, and delivering advanced therapies for people living with serious and complex diseases worldwide. It operates a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA), Alzheimer's disease, and amyotrophic lateral sclerosis (ALS). It is focused on advancing its pipeline in neurology, specialized immunology, and rare diseases. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; SKYCLARYS for the treatment of Friedreich's Ataxia; QALSODY for the treatment of ALS, and FUMADERM for the treatment of severe plaque psoriasis. It also collaborations with Eisai on the commercialization of LEQEMBI for the treatment of Alzheimer's disease and Sage on the commercialization of ZURZUVAE for the treatment of Postpartum Depression (PPD).